Related Experiment Video
Updated: May 11, 2026
Assessing Specificity of Anticancer Drugs In Vitro
Published on: March 23, 2016
[HTA-Perspective: Challenges in the early assessment of new oncological drugs]
Claudia Wild1, Anna Nachtnebel
1Ludwig Boltzmann Institute for Health Technology Assessment, Vienna, Austria. claudia.wild@hta.lbg.ac.at
Abstract:
Oncologic drug therapies have gained wide attention in the context of health policy priority setting for serious and socially significant diseases with high human and monetary costs. Due to uncertainties and scepticism about the actual therapeutic importance of newly approved oncology products, an early assessment programme was already established in Austria in 2007. The assessment of new oncology products is thereby faced with special challenges, since study populations are frequently not representative or the study design is laid out in such a manner that a definitive assessment of patient-relevant endpoints is not possible (cross-overs after interim assessments, surrogate parameters as primary endpoints, uncontrolled studies or those with unrealistic comparators, invalidated post-hoc identified biomarkers). On account of these major uncertainties, even the European Medicines Agency (EMA) is already contemplating multi-stage, "adaptive" approvals, and national reimbursement institutions are increasingly working with outcome-oriented, conditional reimbursement. (As supplied by publisher).
Insights
Early assessment programs for new cancer drugs face challenges due to uncertain evidence. This impacts health policy and reimbursement decisions for oncology therapies.
Area of Science:
- Oncology
- Health Policy
- Pharmacoeconomics
Context:
- Oncologic drug therapies are a health policy priority due to high costs and disease burden.
- Uncertainty regarding the therapeutic value of new oncology drugs necessitates early assessment.
- An early assessment program was established in Austria in 2007 to address these challenges.
Purpose:
- To evaluate the challenges in assessing new oncology products for health policy and reimbursement.
- To highlight the limitations of clinical trial designs in determining patient-relevant endpoints for cancer drugs.
Summary:
- New oncology drug assessments face challenges from non-representative study populations and designs that hinder definitive evaluation of patient-relevant endpoints.
- Issues include interim analyses with cross-overs, surrogate endpoints, and flawed comparator selection or biomarker validation.
- These uncertainties lead regulatory bodies like the European Medicines Agency (EMA) to consider adaptive approvals and reimbursement bodies to opt for conditional reimbursement.
Impact:
- Informs health policy decision-making regarding oncology drug approvals and reimbursement.
- Highlights the need for improved clinical trial methodologies in oncology research.
- Contributes to the discussion on evidence requirements for early access and reimbursement of innovative cancer therapies.
Related Concept Videos
01:11Clinical Trials: Overview
01:26Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:28Preclinical Development: Overview